BLOG/🇺🇸United States··daily

High-Value Federal Grants ($5M+) — February 03, 2026

High-Value Federal Grants ($5M+)

5 total filings analysed

Executive Summary

This $1.13B high-value federal grant stream shows heavy HHS concentration (75% of value across 4 contracts), underscoring sustained federal investment in health R&D, lab expansions, and support services through 2028. Hensel Phelps emerges as a standout with $457M in bullish construction wins for GSA and NIH facilities. Overall bullish signals (4/5) highlight revenue visibility via full obligations and high outlays ($100M+ in two cases), though low initial spends in some signal execution ramps.

Tracking the trend? Catch up on the prior High-Value Federal Grants ($5M+) digest from February 02, 2026.

Investment Signals(3)

  • Hensel Phelps $457M construction backlog(HIGH)

    Dual wins totaling $457M fully obligated with $144M outlayed signal strong positioning in gov't building projects ending 2026-2028.

  • HHS services revenue acceleration(HIGH)

    GD IT and Emmes secure $366M combined with $220M outlayed in CMS/NIH support and data services, indicating mature execution in health admin/IT.

  • Slow biotech manufacturing ramp(MEDIUM)

    ATI's $304M BARDA award has minimal $11M outlay despite full obligation, tempering near-term upside in biological products.

Risk Flags(2)

  • Execution[HIGH RISK]

    Firm-fixed price exposes Hensel Phelps to $457M cost overruns in design-build/lab projects amid low initial outlays ($21M/$277M, $57M remaining/$180M).

  • Regulatory[MEDIUM RISK]

    Long tenors to 2028 (all contracts) vulnerable to HHS/GSA budget shifts; cost-plus structures (3/5) invite audits capping fees.

Opportunities(2)

  • $192M unexercised options across ATI ($72M), GD IT ($2M), Emmes ($117M) plus extensions to 2028.

  • HHS lab/infectious disease focus ($653M) positions winners for follow-on R&D work post-2026/2028 completions.

Sector Themes(2)

  • 75% of value ($849M) in HHS awards for labs, data services, and manufacturing signals multi-year federal priority on biomedical readiness.

  • Two Hensel Phelps wins ($457M) in border/lab facilities highlight full obligation visibility through 2028.

Watch List(2)

  • 👁

    {"entity"=>"Hensel Phelps Construction Co.", "reason"=>"$457M backlog with $144M outlayed positions for follow-ons in GSA/NIH projects.", "trigger"=>"Outlays exceeding 50% ($228M total) or new awards >$100M"}

  • 👁

    {"entity"=>"HHS Budget Allocations", "reason"=>"Dominates stream; changes could impact $849M pipeline to 2028.", "trigger"=>"FY2027 appropriations cuts or BARDA/NIH expansions"}

Get daily alerts with 3 investment signals, 2 risk alerts, 2 opportunities and full AI analysis of all 5 filings

🇺🇸 More from United States

View all →
High-Value Federal Grants ($5M+) — February 03, 2026 | Gunpowder Blog